Teladoc Health, Inc. (TDOC)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Teladoc Health, Inc. (“Teladoc Health” or “the Company”) (NYSE: TDOC). Investors who purchased Teladoc Health securities are encouraged to obtain additional information and assist the investigation.

The investigation concerns whether Teladoc Health has violated federal securities laws.

Teladoc Health Investigation Details

Teladoc Health, Inc. reported second quarter 2026 financial results, posting consolidated revenue of $606.9 million, below analyst expectations, and lowered its full-year 2026 revenue guidance to $2.36 billion to $2.45 billion, down from the $2.48 billion to $2.57 billion range it had reaffirmed following first quarter 2026 results. Earlier, on February 25, 2026, the Company had guided for full-year revenue of $2.47 billion to $2.59 billion and projected that BetterHelp revenue would decline 7% to 0.5%. On April 29, 2026, Teladoc narrowed those ranges, forecasting full-year revenue of approximately $2.48 billion to $2.57 billion and BetterHelp revenue to decline 6.5% to 1%. On the July 29, 2026 earnings call, Chief Executive Officer Charles Divita acknowledged that the Company’s prior BetterHelp outlook had assumed it would successfully scale its insurance business while stabilizing and growing overall BetterHelp revenue, but disclosed that the “decline in cash pay users … accelerated beyond the decline incorporated in our prior outlook” and that insurance capacity “did not expand at the same pace as the increase in demand.” Following this news, Teladoc Health’s stock price dropped more than 28% on July 30, 2026.

What’s Next for Teladoc Health Investors?

If you are aware of any facts relating to this investigation or purchased Teladoc Health securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911

No Cost to Teladoc Health Investors

We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC For Teladoc Health Securities Investigation?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace,” said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]

Attorney advertising.
Prior results do not guarantee similar outcomes.